# First-in-Human Single Ascending and Multiple Dose of GLPG0634

> **NCT01179581** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG0634
- **DRUG:** placebo
- **DRUG:** GLPG0634
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01179581
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01179581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01179581, "First-in-Human Single Ascending and Multiple Dose of GLPG0634". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01179581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*